IBDEI01U ; ; 06-AUG-2013
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;AUG 06, 2013
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,1988,2)
 ;;=^329909
 ;;^UTILITY(U,$J,358.3,1989,0)
 ;;=282.43^^23^165^4
 ;;^UTILITY(U,$J,358.3,1989,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1989,1,1,0)
 ;;=1^282.43
 ;;^UTILITY(U,$J,358.3,1989,1,8,0)
 ;;=8^Alpha Thalessemia
 ;;^UTILITY(U,$J,358.3,1989,2)
 ;;=^340494
 ;;^UTILITY(U,$J,358.3,1990,0)
 ;;=282.44^^23^165^12
 ;;^UTILITY(U,$J,358.3,1990,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1990,1,1,0)
 ;;=1^282.44
 ;;^UTILITY(U,$J,358.3,1990,1,8,0)
 ;;=8^Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,1990,2)
 ;;=^340495
 ;;^UTILITY(U,$J,358.3,1991,0)
 ;;=282.45^^23^165^14
 ;;^UTILITY(U,$J,358.3,1991,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1991,1,1,0)
 ;;=1^282.45
 ;;^UTILITY(U,$J,358.3,1991,1,8,0)
 ;;=8^Delta-beta Thalassemia
 ;;^UTILITY(U,$J,358.3,1991,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,1992,0)
 ;;=282.46^^23^165^49
 ;;^UTILITY(U,$J,358.3,1992,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1992,1,1,0)
 ;;=1^282.46
 ;;^UTILITY(U,$J,358.3,1992,1,8,0)
 ;;=8^Thalassemia Minor
 ;;^UTILITY(U,$J,358.3,1992,2)
 ;;=^340497
 ;;^UTILITY(U,$J,358.3,1993,0)
 ;;=282.47^^23^165^18
 ;;^UTILITY(U,$J,358.3,1993,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1993,1,1,0)
 ;;=1^282.47
 ;;^UTILITY(U,$J,358.3,1993,1,8,0)
 ;;=8^Hemoglobin E-beta Thalassemia
 ;;^UTILITY(U,$J,358.3,1993,2)
 ;;=^340498
 ;;^UTILITY(U,$J,358.3,1994,0)
 ;;=282.49^^23^165^38
 ;;^UTILITY(U,$J,358.3,1994,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1994,1,1,0)
 ;;=1^282.49
 ;;^UTILITY(U,$J,358.3,1994,1,8,0)
 ;;=8^Oth Thalassemia
 ;;^UTILITY(U,$J,358.3,1994,2)
 ;;=^329910
 ;;^UTILITY(U,$J,358.3,1995,0)
 ;;=282.5^^23^165^45
 ;;^UTILITY(U,$J,358.3,1995,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1995,1,1,0)
 ;;=1^282.5
 ;;^UTILITY(U,$J,358.3,1995,1,8,0)
 ;;=8^Sickle-cell Trait
 ;;^UTILITY(U,$J,358.3,1995,2)
 ;;=^110419
 ;;^UTILITY(U,$J,358.3,1996,0)
 ;;=282.60^^23^165^43
 ;;^UTILITY(U,$J,358.3,1996,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1996,1,1,0)
 ;;=1^282.60
 ;;^UTILITY(U,$J,358.3,1996,1,8,0)
 ;;=8^Sickle-cell Disease Unspec
 ;;^UTILITY(U,$J,358.3,1996,2)
 ;;=^330077
 ;;^UTILITY(U,$J,358.3,1997,0)
 ;;=282.62^^23^165^16
 ;;^UTILITY(U,$J,358.3,1997,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1997,1,1,0)
 ;;=1^282.62
 ;;^UTILITY(U,$J,358.3,1997,1,8,0)
 ;;=8^Hb-SS Disease w/ Crisis
 ;;^UTILITY(U,$J,358.3,1997,2)
 ;;=^330079
 ;;^UTILITY(U,$J,358.3,1998,0)
 ;;=282.61^^23^165^17
 ;;^UTILITY(U,$J,358.3,1998,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1998,1,1,0)
 ;;=1^282.61
 ;;^UTILITY(U,$J,358.3,1998,1,8,0)
 ;;=8^Hb-SS Disease w/o Crisis
 ;;^UTILITY(U,$J,358.3,1998,2)
 ;;=^330078
 ;;^UTILITY(U,$J,358.3,1999,0)
 ;;=282.63^^23^165^47
 ;;^UTILITY(U,$J,358.3,1999,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,1999,1,1,0)
 ;;=1^282.63
 ;;^UTILITY(U,$J,358.3,1999,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,1999,2)
 ;;=^330080
 ;;^UTILITY(U,$J,358.3,2000,0)
 ;;=282.64^^23^165^46
 ;;^UTILITY(U,$J,358.3,2000,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2000,1,1,0)
 ;;=1^282.64
 ;;^UTILITY(U,$J,358.3,2000,1,8,0)
 ;;=8^Sickle-cell/Hb-C Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,2000,2)
 ;;=^329911
 ;;^UTILITY(U,$J,358.3,2001,0)
 ;;=282.68^^23^165^34
 ;;^UTILITY(U,$J,358.3,2001,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2001,1,1,0)
 ;;=1^282.68
 ;;^UTILITY(U,$J,358.3,2001,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/o Crisis
 ;;^UTILITY(U,$J,358.3,2001,2)
 ;;=^329912
 ;;^UTILITY(U,$J,358.3,2002,0)
 ;;=282.69^^23^165^33
 ;;^UTILITY(U,$J,358.3,2002,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2002,1,1,0)
 ;;=1^282.69
 ;;^UTILITY(U,$J,358.3,2002,1,8,0)
 ;;=8^Oth Sickle-cell Dis w/ Crisis
 ;;^UTILITY(U,$J,358.3,2002,2)
 ;;=^330081
 ;;^UTILITY(U,$J,358.3,2003,0)
 ;;=282.7^^23^165^30
 ;;^UTILITY(U,$J,358.3,2003,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2003,1,1,0)
 ;;=1^282.7
 ;;^UTILITY(U,$J,358.3,2003,1,8,0)
 ;;=8^Oth Hemoglobinopathies
 ;;^UTILITY(U,$J,358.3,2003,2)
 ;;=^87629
 ;;^UTILITY(U,$J,358.3,2004,0)
 ;;=282.8^^23^165^36
 ;;^UTILITY(U,$J,358.3,2004,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2004,1,1,0)
 ;;=1^282.8
 ;;^UTILITY(U,$J,358.3,2004,1,8,0)
 ;;=8^Oth Spec Hereditary Hemolytic
 ;;^UTILITY(U,$J,358.3,2004,2)
 ;;=^267984
 ;;^UTILITY(U,$J,358.3,2005,0)
 ;;=283.10^^23^165^27
 ;;^UTILITY(U,$J,358.3,2005,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2005,1,1,0)
 ;;=1^283.10
 ;;^UTILITY(U,$J,358.3,2005,1,8,0)
 ;;=8^Non-autoimmune Hemolytic Anemia
 ;;^UTILITY(U,$J,358.3,2005,2)
 ;;=^294004
 ;;^UTILITY(U,$J,358.3,2006,0)
 ;;=283.11^^23^165^21
 ;;^UTILITY(U,$J,358.3,2006,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2006,1,1,0)
 ;;=1^283.11
 ;;^UTILITY(U,$J,358.3,2006,1,8,0)
 ;;=8^Hemolytic-uremic Syndrome
 ;;^UTILITY(U,$J,358.3,2006,2)
 ;;=^293663
 ;;^UTILITY(U,$J,358.3,2007,0)
 ;;=285.0^^23^165^48
 ;;^UTILITY(U,$J,358.3,2007,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2007,1,1,0)
 ;;=1^285.0
 ;;^UTILITY(U,$J,358.3,2007,1,8,0)
 ;;=8^Sideroblastic Anemia
 ;;^UTILITY(U,$J,358.3,2007,2)
 ;;=^7204
 ;;^UTILITY(U,$J,358.3,2008,0)
 ;;=285.3^^23^165^9
 ;;^UTILITY(U,$J,358.3,2008,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2008,1,1,0)
 ;;=1^285.3
 ;;^UTILITY(U,$J,358.3,2008,1,8,0)
 ;;=8^Antineoplastic Chemo Ind Anemia
 ;;^UTILITY(U,$J,358.3,2008,2)
 ;;=^338232
 ;;^UTILITY(U,$J,358.3,2009,0)
 ;;=285.8^^23^165^35
 ;;^UTILITY(U,$J,358.3,2009,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2009,1,1,0)
 ;;=1^285.8
 ;;^UTILITY(U,$J,358.3,2009,1,8,0)
 ;;=8^Oth Spec Anemia
 ;;^UTILITY(U,$J,358.3,2009,2)
 ;;=^87876
 ;;^UTILITY(U,$J,358.3,2010,0)
 ;;=283.2^^23^165^20
 ;;^UTILITY(U,$J,358.3,2010,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2010,1,1,0)
 ;;=1^283.2
 ;;^UTILITY(U,$J,358.3,2010,1,8,0)
 ;;=8^Hemolytic d/t Hemolysis
 ;;^UTILITY(U,$J,358.3,2010,2)
 ;;=^55770
 ;;^UTILITY(U,$J,358.3,2011,0)
 ;;=286.9^^23^166^11
 ;;^UTILITY(U,$J,358.3,2011,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2011,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,2011,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,2011,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,2012,0)
 ;;=446.6^^23^166^28
 ;;^UTILITY(U,$J,358.3,2012,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2012,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,2012,1,8,0)
 ;;=8^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,2012,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,2013,0)
 ;;=451.9^^23^166^27
 ;;^UTILITY(U,$J,358.3,2013,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2013,1,1,0)
 ;;=1^451.9
 ;;^UTILITY(U,$J,358.3,2013,1,8,0)
 ;;=8^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,2013,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,2014,0)
 ;;=287.5^^23^166^25
 ;;^UTILITY(U,$J,358.3,2014,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2014,1,1,0)
 ;;=1^287.5
 ;;^UTILITY(U,$J,358.3,2014,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,2014,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,2015,0)
 ;;=287.1^^23^166^23
 ;;^UTILITY(U,$J,358.3,2015,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2015,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,2015,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,2015,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,2016,0)
 ;;=287.30^^23^166^22
 ;;^UTILITY(U,$J,358.3,2016,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2016,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,2016,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,2016,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,2017,0)
 ;;=238.71^^23^166^26
 ;;^UTILITY(U,$J,358.3,2017,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2017,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,2017,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,2017,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,2018,0)
 ;;=286.52^^23^166^2
 ;;^UTILITY(U,$J,358.3,2018,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2018,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,2018,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,2018,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,2019,0)
 ;;=286.53^^23^166^5
 ;;^UTILITY(U,$J,358.3,2019,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2019,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,2019,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,2019,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,2020,0)
 ;;=286.59^^23^166^16
 ;;^UTILITY(U,$J,358.3,2020,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2020,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,2020,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,2020,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,2021,0)
 ;;=286.0^^23^166^9
 ;;^UTILITY(U,$J,358.3,2021,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2021,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,2021,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,2021,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,2022,0)
 ;;=286.1^^23^166^7
 ;;^UTILITY(U,$J,358.3,2022,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2022,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,2022,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,2022,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,2023,0)
 ;;=286.2^^23^166^10
 ;;^UTILITY(U,$J,358.3,2023,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2023,1,1,0)
 ;;=1^286.2
 ;;^UTILITY(U,$J,358.3,2023,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,2023,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,2024,0)
 ;;=286.3^^23^166^8
 ;;^UTILITY(U,$J,358.3,2024,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2024,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,2024,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,2024,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,2025,0)
 ;;=286.4^^23^166^30
 ;;^UTILITY(U,$J,358.3,2025,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2025,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,2025,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,2025,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,2026,0)
 ;;=286.52^^23^166^3
 ;;^UTILITY(U,$J,358.3,2026,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,2026,1,1,0)
 ;;=1^286.52
